The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor.

In a recently completed randomised phase 2a clinical trial involving 30 subjects with heart failure (NCT04192214), treatment with rovunaptabin was found to be safe and well tolerated. Furthermore, the study showed promising improvements in cardiac performance, as measured by left ventricular ejection fraction (LVEF), in patients who received the treatment.
Further clinical investigator-initiated trials are planned to confirm these results in a larger cohort of patients and the company hopes to initiate trials in 2027.